Aldeyra Therapeutics, Inc. (ALDX) stock
ALDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.67+0.03 (+4.01%)
Close on Nov 16, 2026Market cap $40.39MP/E –Yield –
Aldeyra Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Aldeyra Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $15.63M, down 63.7% year over year. For fiscal 2025 it was $25.66M, down 46.8% from the year before. Over ten years it grew 13.0% a year on average. The highest annual figure on record is $48.22M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.66M | -46.8% |
| FY2024 | Dec 31, 2024 | $48.22M | +63.7% |
| FY2023 | Dec 31, 2023 | $29.46M | -37.7% |
| FY2022 | Dec 31, 2022 | $47.31M | +5.3% |
| FY2021 | Dec 31, 2021 | $44.94M | +82.1% |
| FY2020 | Dec 31, 2020 | $24.68M | -44.4% |
| FY2019 | Dec 31, 2019 | $44.35M | +48.7% |
| FY2018 | Dec 31, 2018 | $29.82M | +82.9% |
| FY2017 | Dec 31, 2017 | $16.30M | +23.7% |
| FY2016 | Dec 31, 2016 | $13.18M | +74.0% |
| FY2015 | Dec 31, 2015 | $7.57M | +104.3% |
| FY2014 | Dec 31, 2014 | $3.71M | +140.5% |
| FY2013 | Dec 31, 2013 | $1.54M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.48M | -59.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.41M | -67.5% |
| Q4 FY2025 | Dec 31, 2025 | $4.30M | -70.6% |
| Q3 FY2025 | Sep 30, 2025 | $5.43M | -56.3% |
| Q2 FY2025 | Jun 30, 2025 | $8.51M | -43.2% |
| Q1 FY2025 | Mar 31, 2025 | $7.42M | +20.1% |
| Q4 FY2024 | Dec 31, 2024 | $14.63M | +240.4% |
| Q3 FY2024 | Sep 30, 2024 | $12.44M | +78.7% |
| Q2 FY2024 | Jun 30, 2024 | $14.97M | +115.0% |
| Q1 FY2024 | Mar 31, 2024 | $6.18M | -45.0% |
| Q4 FY2023 | Dec 31, 2023 | $4.30M | -52.0% |
| Q3 FY2023 | Sep 30, 2023 | $6.96M | -39.7% |
| Q2 FY2023 | Jun 30, 2023 | $6.96M | -52.2% |
| Q1 FY2023 | Mar 31, 2023 | $11.24M | -8.2% |
| Q4 FY2022 | Dec 31, 2022 | $8.96M | -30.2% |
| Q3 FY2022 | Sep 30, 2022 | $11.54M | -10.5% |
| Q2 FY2022 | Jun 30, 2022 | $14.57M | +27.0% |
| Q1 FY2022 | Mar 31, 2022 | $12.23M | +58.3% |
| Q4 FY2021 | Dec 31, 2021 | $12.84M | +82.7% |
| Q3 FY2021 | Sep 30, 2021 | $12.89M | +110.2% |
| Q2 FY2021 | Jun 30, 2021 | $11.47M | +134.8% |
| Q1 FY2021 | Mar 31, 2021 | $7.73M | +16.5% |
| Q4 FY2020 | Dec 31, 2020 | $7.03M | -26.9% |
| Q3 FY2020 | Sep 30, 2020 | $6.13M | -62.2% |
| Q2 FY2020 | Jun 30, 2020 | $4.89M | -54.2% |
| Q1 FY2020 | Mar 31, 2020 | $6.63M | -15.5% |
| Q4 FY2019 | Dec 31, 2019 | $9.61M | +12.5% |
| Q3 FY2019 | Sep 30, 2019 | $16.22M | +105.9% |
| Q2 FY2019 | Jun 30, 2019 | $10.66M | +92.3% |
| Q1 FY2019 | Mar 31, 2019 | $7.85M | +121.8% |
| Q4 FY2018 | Dec 31, 2018 | $8.55M | +122.1% |
| Q3 FY2018 | Sep 30, 2018 | $7.88M | +133.9% |
| Q4 FY2017 | Dec 31, 2017 | $5.55M | +60.9% |
| Q3 FY2017 | Sep 30, 2017 | $3.54M | +4.7% |
| Q2 FY2017 | Jun 30, 2017 | $3.85M | +35.8% |
| Q1 FY2017 | Mar 31, 2017 | $3.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.45M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.38M | – |
| Q2 FY2016 | Jun 30, 2016 | $2.83M | – |
See a number that looks wrong?